Price: $7.7400
$0.16
2.111%
|
Day's High:
| $8.168
| Week Perf:
| -5.65 %
|
Day's Low: |
$ 7.53 |
30 Day Perf: |
-9.79 % |
Volume (M): |
13 |
52 Wk High: |
$ 10.25 |
Volume (M$): |
$ 98 |
52 Wk Avg: |
$8.13 |
Open: |
$7.71 |
52 Wk Low: |
$5.79 |
|
|
Market Capitalization (Millions $) |
36 |
Shares
Outstanding (Millions) |
5 |
Employees |
34 |
Revenues (TTM) (Millions $) |
11 |
Net Income (TTM) (Millions $) |
3 |
Cash Flow (TTM) (Millions $) |
7 |
Capital Exp. (TTM) (Millions $) |
0 |
United Guardian Inc
United-Guardian, Inc. is a Delaware corporation that, through its Guardian
Laboratories Division ("Guardian"), manufactures and markets cosmetic
ingredients, personal care products, pharmaceuticals, medical lubricants, health
care products, and specialty industrial products. It also conducts research
and product development, primarily related to the development of new and unique
cosmetic and personal care products. The Company’s research and development
department also modifies, refines, and expands the uses for existing products,
with the goal of further developing the market for the Companys products.
Uniteds predecessor, United International Research, Inc. ("UIR"),
was founded and incorporated in New York in 1942 by Dr. Alfred R. Globus, Uniteds
Chairman and Director of Research until his death on April 9, 2009. On February
10, 1982, a merger took place between UIR and Guardian Chemical Corp. ("GCC"),
an affiliate of UIR, whereby GCC was merged into UIR and the name was changed
to United-Guardian, Inc., a New York corporation. On September 14, 1987, United-Guardian,
Inc. (New York) was merged with and into a newly-formed Delaware corporation
by the same name, United-Guardian, Inc., for the purpose of changing the domicile
of the Company to Delaware.
The Company manufactures and markets cosmetic ingredients, personal and health
care products, medical lubricants, pharmaceuticals, and specialty industrial
products. It also conducts research and development, primarily related to the
development of new and unique cosmetic and personal care products. The Company
focuses on the development of products that fill unmet market needs, have unique
properties, and use proprietary technology that it sometimes protects with patents.
Many of the Companys products are marketed through collaborative agreements
with larger companies. The personal care products manufactured by the Company,
including the cosmetic ingredients, are marketed to end users through the Companys
worldwide network of marketing partners and distributors, and are currently
used by many of the major manufacturers of cosmetic and personal care products.
The Company sells product outright to its marketing partners, Ex Works (EXW)
the Company’s plant in Hauppauge, New York. Those marketing partners in
turn resell those products to their customers, who are typically the manufacturers
and marketers of cosmetic and personal care products, and who in turn utilize
the Company’s products in their finished products. The products are not
sold on a consignment basis, so unless a product is determined to be defective
it is not returnable except at the discretion of the Company.
The Company operates in one business segment. The Company’s products
are separated into four distinct product categories: personal care products
(including cosmetic ingredients), pharmaceuticals, medical products, and industrial
products. Each product category is marketed differently.
The Company’s personal care products, including cosmetic ingredients,
are marketed globally by six marketing partners, of which Ashland Specialty
Ingredients (“ASI”), a business segment of Ashland, Inc., is the
largest. The products are sold directly to those marketing partners, which in
turn resell those products to its customers for use in the manufacture or compounding
of the customers’ personal care and cosmetic products. The Company’s
non-pharmaceutical medical products (referred to hereinafter as “medical
products”) and the specialty industrial products are sold directly by
the Company to the end users or to contract manufacturers utilized by the end
users. The Company’s pharmaceutical products are marketed by direct advertising,
mailings, and trade exhibitions, and are sold to hospitals and pharmacies primarily
through full-line drug wholesalers, which purchase the Company’s products
outright for resale to their customers. The Company also sells a small quantity
of pharmaceutical products directly to hospitals and pharmacies. The Companys
products are sold under trademarks or trade names owned by the Company, some
of which are registered with the United States Patent and Trademark Office as
well as comparable regulatory agencies in some foreign countries.
Company Address: 230 Marcus Boulevard Hauppauge 11788 NY
Company Phone Number: 273-0900 Stock Exchange / Ticker: NASDAQ UG
UG is expected to report next financial results on March 22, 2024. |
|
|
|
Customers Net Income fell by |
UG's Customers Net Profit Margin fell to |
-7.61 % |
13.39 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
United Guardian Inc
United Guardian Inc, a leading company in the Personal & Household Products industry, showcased impressive growth in its financial report for the quarter ending September 30, 2023. The company experienced a remarkable increase of 100% in income per share, reaching $0.14 per share. Additionally, its revenue surged by 26.499% to reach $3.06 million. This outstanding performance demonstrates that United Guardian Inc has outperformed its industry peers in terms of revenue growth. While the Personal & Household Products industry reported a revenue improvement of only 3.22% during the same period, United Guardian Inc achieved a substantial 26.499% growth. Furthermore, United Guardian Inc witnessed a significant improvement in profitability, as its income per share grew by 40% from $0.10 per share in the previous year. The company also experienced a 15.365% increase in revenue, reaching $2.65 million. These figures indicate that United Guardian Inc continues to prosper despite the challenges it faces in the demanding supplier climate.
|
United Guardian Inc
During the past 5 trading days, United Guardian Inc's stock experienced a drop of -0.51%, resulting in a year-to-date performance of -26.25%. However, despite this recent decline, the stock is still trading 8.3% above its 52-week low. Looking at the financial performance of United Guardian Inc in the second quarter of 2023, there are some concerning indicators. The net profit per share dropped by -28.57% to $0.10 per share compared to $0.14 a year prior. Additionally, the income faded by -37.5% from $0.16 per share in the previous quarter. The revenue of United Guardian Inc also experienced a decline, decreasing by -26.912% to $2.65 million in the second quarter of 2023 compared to $3.63 million in the same quarter a year before. However, sequentially, the revenue increased by 3.111% from $2.57 million. The net profits in the second quarter of 2023 fell by -27.19% to $0.461 million compared to break-even in the corresponding period a year earlier. Examining the profitability margins, United Guardian Inc's operating margin mitigated to 19.55% in the second quarter of 2023, and the net margin shrank to 17.4%. These figures indicate a decrease in the company's profitability. Due to the seasonal nature of the business, the inventories of United Guardian Inc have declined to $1.8 million from the previous quarter, although this still marks an increase relative to the same period a year ago. Moreover, the operating earnings fell by -56.82% to $0.51807 million, resulting in a decline in the operating margin to 19.55% from 33.09% in the second quarter of 2022.
|
United Guardian Inc
United Guardian Inc, a company in the Consumer Non-Cyclical sector, has released their financial results for the fiscal time-frame ending March 31, 2023. The company's income has fallen by 20% from $0.20 per share in the previous year to $0.16 per share, whereas, income has improved by 8.23% from $0.15 per share from the previous period of reporting. This highlights a decline in the company's income, indicating weak financial performance in the current year. Similarly, the revenue of the company has fallen significantly by 33.965% to $2.57 million compared to $3.89 million in the previous year, and sequentially revenue saw a decrease of 6.972% from $2.76 million. These declines indicate a weak demand for the company's products and services, which has led to a decline in revenue.
|
Per Share |
Current |
Earnings (TTM) |
0.55 $ |
Revenues (TTM) |
2.4 $
|
Cash Flow (TTM) |
1.44 $ |
Cash |
1.75 $
|
Book Value |
2.32 $
|
Dividend (TTM) |
0.41 $ |
|
Per Share |
|
Earnings (TTM) |
0.55 $
|
Revenues (TTM) |
2.4 $ |
Cash Flow (TTM) |
1.44 $ |
Cash |
1.75 $
|
Book Value |
2.32 $ |
Dividend (TTM) |
0.41 $ |
|
|
|
|